Cargando…

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression

The ATP-binding cassette family of transporter proteins, subfamily B (MDR/TAP), member 1 (ABCB1) (P-glycoprotein) transporter is a key component of the blood–brain barrier. Many antidepressants are subject to ABCB1 efflux. Functional polymorphisms of ABCB1 may influence central nervous system bioava...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, A B, Bousman, C A, Ng, C H, Byron, K, Berk, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565756/ https://www.ncbi.nlm.nih.gov/pubmed/23188198 http://dx.doi.org/10.1038/tp.2012.115

Ejemplares similares

Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
por: Bousman, Chad A., et al.
Publicado: (2017)

Sexual functioning in females with depression in remission receiving escitalopram
por: Roy, Pritha, et al.
Publicado: (2019)

Effects of Persisting Emotional Impact from Child Abuse and Norepinephrine Transporter Genetic Variation on Antidepressant Efficacy in Major Depression: A Pilot Study
por: Singh, Ajeet Bhagat, et al.
Publicado: (2015)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression
por: Bernini de Brito, Rodrigo, et al.
Publicado: (2020)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011)

Effect of Escitalopram on White Blood Cells in Patients With Major Depression
por: Canan, Fatih, et al.
Publicado: (2009)

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
por: Mencacci, Claudio, et al.
Publicado: (2013)

CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression
por: Han, Kyu-Man, et al.
Publicado: (2013)

Lower serum brain-derived neurotrophic factor levels are associated with failure to achieve remission in patients with major depression after escitalopram treatment
por: Lee, Bun-Hee, et al.
Publicado: (2014)

Cognitive remission: a novel objective for the treatment of major depression?
por: Bortolato, Beatrice, et al.
Publicado: (2016)

Association between ABCB1 Polymorphisms and Antidepressant Treatment Response in Taiwanese Major Depressive Patients
por: Chang, Hui Hua, et al.
Publicado: (2015)

Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression
por: Leonard, Brian, et al.
Publicado: (2010)

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
por: Alkahtani, Manal E., et al.
Publicado: (2021)

quality of remission in the major depressive disorder
por: Chebli, H., et al.
Publicado: (2023)

Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
por: Wade, Alan G, et al.
Publicado: (2011)

3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders
por: Avram, Speranta, et al.
Publicado: (2010)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
por: MahmoudianDehkordi, Siamak, et al.
Publicado: (2021)

Association Between ABCB1 Polymorphism and Stable Warfarin Dose Requirements in Brazilian Patients
por: Tavares, Letícia C., et al.
Publicado: (2018)

Unilateral Galactorrhea Associated with Low-dose Escitalopram
por: Ravi, P. Bangalore, et al.
Publicado: (2014)

Predicting escitalopram monotherapy response in depression: The role of anterior cingulate cortex
por: Tian, Shui, et al.
Publicado: (2019)

Left DLPFC activity is associated with plasma kynurenine levels and can predict treatment response to escitalopram in major depressive disorder
por: Kamishikiryo, Toshiharu, et al.
Publicado: (2022)

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder
por: Martens, Marieke A. G., et al.
Publicado: (2021)

Depression in Acromegaly Treated with Escitalopram and Cognitive Therapy
por: De Sousa, Avinash
Publicado: (2009)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability
por: Kirino, Eiji
Publicado: (2012)

Comparing the Effects of Bupropion and Escitalopram on Excessive Internet Game Play in Patients with Major Depressive Disorder
por: Nam, Beomwoo, et al.
Publicado: (2017)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Escitalopram-induced akathisia in a patient with major depressive disorder: A rare case report
por: Arshad, Hareem, et al.
Publicado: (2022)

Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder
por: Sun, Zuoli, et al.
Publicado: (2023)

Unraveling the Potential of Isorhamnetin as an Adjuvant in Depression Treatment with Escitalopram
por: Gammoh, Omar, et al.
Publicado: (2023)

Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong, Jong-Hyun, et al.
Publicado: (2015)

Prediction of remission in pharmacotherapy of untreated major depression: development and validation of multivariable prediction models
por: Furukawa, Toshi A., et al.
Publicado: (2019)

Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults
por: Polychroniou, Philip E., et al.
Publicado: (2018)

Intrinsic connectomes are a predictive biomarker of remission in major depressive disorder
por: Korgaonkar, Mayuresh S., et al.
Publicado: (2019)

The effect of a single dose of escitalopram on sensorimotor networks
por: Weisstanner, Christian, et al.
Publicado: (2018)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o3oaiffel3qdjuuv8i6e4n3pnf